7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality

Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality

In clinical hematology, analytical accuracy depends entirely on specimen integrity. Up to 70% of all diagnostic laboratory errors occur during the preanalytical phase—encompassing patient preparation, venipuncture technique, anticoagulant selection, tube filling volume, specimen mixing, transport, and storage. Because modern hematology analyzers measure subtle cellular volumes down to fractions of a femtoliter ($10^{-15}\text{ L}$) and evaluate delicate optical scatter patterns, minor preanalytical deviations produce profound diagnostic errors, misclassifying anemias, falsely triggering acute leukemia flags, or masking severe thrombocytopenia.

                         ┌────────────────────────────────────────────────────────┐
                         │   Hematology Specimen Collection & Anticoagulant Tree  │
                         └───────────────────────────┬────────────────────────────┘
                                                     │
                         ┌───────────────────────────┴───────────────────────────┐
                         ▼                                                       ▼
         ┌───────────────────────────────┐                       ┌───────────────────────────────┐
         │  Lavender Top: EDTA Tube      │                       │  Light Blue: Sodium Citrate   │
         │  (Routine CBC, Indices, Smear)│                       │  (Coagulation: PT, aPTT, TT)  │
         └───────────────┬───────────────┘                       └───────────────┬───────────────┘
                         │                                                       │
         ┌───────────────┴───────────────┐                       ┌───────────────┴───────────────┐
         ▼                               ▼                       ▼                               ▼
  ┌──────────────┐                ┌──────────────┐        ┌──────────────┐                ┌──────────────┐
  │Spray-Dried   │                │ Liquid       │        │  Strict 9:1  │                │ Hct > 55%    │
  │K2EDTA (ICSH) │                │ K3EDTA       │        │  Whole Blood │                │ Polycythemia │
  │1.5-2.2 mg/mL │                │1-2% Dilution │        │  to Citrate  │                │ Correction   │
  └──────┬───────┘                └──────┬───────┘        └──────┬───────┘                └──────┬───────┘
         │                               │                       │                               │
  • Preserves RBC volume          • Shrinks RBCs          • 3.2% (0.109 M)        • C = 1.85 x 10^-3     
  • Best for cell sizing          • Underfill = artifact    buffered citrate        x (100 - Hct) x V    
  • Chelation of Ca2+             • Chelation of Ca2+     • Underfill = ↑ PT/aPTT • Prevents false ↑ PT  

---

1. Hematology Anticoagulants: EDTA Formulations and Mechanics

Ethylenediaminetetraacetic acid (EDTA) is the universally accepted anticoagulant for routine Complete Blood Counts (CBC), erythrocyte indices, and peripheral blood smear evaluations.

Biochemical Mechanism of Action

EDTA functions by chelating divalent ionized calcium ($Ca^{2+}$), forming a stable, non-ionizable soluble complex. Because calcium is an indispensable cofactor (Factor IV) in the intrinsic, extrinsic, and common coagulation cascades—required for the activation of Factor IX, Factor X, and prothrombin conversion to thrombin—its removal halts the clotting cascade at its earliest stages. Simultaneously, calcium chelation suppresses calcium-dependent platelet activation and aggregation, maintaining erythrocytes, leukocytes, and platelets in an unaggregated, free-floating suspension.

Chemical Formulations: $K_2\text{EDTA}$ vs. $K_3\text{EDTA}$ vs. $Na_2\text{EDTA}$

Three primary formulations of EDTA have been utilized in vacutainer tubes, but their physiological and analytical behaviors differ substantially:

1. Dipotassium EDTA ($K_2\text{EDTA}$):

   • Physical State: Spray-dried onto the interior glass or plastic tube walls.
   • Optimal Concentration: $1.5\text{ to }2.2\text{ mg}$ per milliliter of whole blood (the ICSH range, about $3.4\text{ to }5.0\text{ mmol/L}$).
   • Clinical Recommendation: Recommended by both the International Council for Standardization in Haematology (ICSH) and the Clinical and Laboratory Standards Institute (CLSI) as the gold standard anticoagulant for automated hematology cell counting and sizing.
   • Analytical Advantage: Because it is spray-dried, it introduces zero liquid volume, avoiding any specimen dilution. Furthermore, $K_2\text{EDTA}$ has a minimal hyperosmolar effect on erythrocytes, preserving true Mean Corpuscular Volume ($MCV$) within $1\%$ of baseline for up to 24 hours.

2. Tripotassium EDTA ($K_3\text{EDTA}$):

   • Physical State: Dispensed as a concentrated liquid solution.
   • Analytical Drawbacks: Liquid $K_3\text{EDTA}$ causes an obligatory $1\%\text{ to }2\%$ dilutional decrease in all measured cellular concentrations (RBC count, WBC count, hemoglobin, and hematocrit). More significantly, tripotassium EDTA exerts an uncompensated hypertonic osmotic draw, pulling intracellular water out of erythrocytes. This produces progressive erythrocyte shrinkage, artifactually depressing the $MCV$ by $2\%\text{ to }3\%$ compared to $K_2\text{EDTA}$.

3. Disodium EDTA ($Na_2\text{EDTA}$):

   • Rarely used in modern clinical practice due to its poor water solubility, requiring prolonged dissolution times that risk partial microclot formation.

Analytical Effects of Tube Underfilling

Underfilling an EDTA tube (collecting less than $80\%$ of the nominal fill volume) produces an abnormally high concentration of EDTA relative to blood volume:

• Erythrocyte Shrinkage: High EDTA concentration creates a hypertonic extracellular plasma environment. Free water exits the red cells via osmosis, causing cellular dehydration and shrinkage.
• Falsely Decreased MCV and Hematocrit: Automated cell counters measure smaller voltage or light scatter pulses, reducing the measured $MCV$. Because automated hematocrit is calculated as $(\text{RBC} \times \text{MCV}) / 10$, hematocrit drops artifactually.
• Falsely Elevated MCHC: Since cellular hemoglobin mass remains constant while the measured red cell volume decreases, the calculated Mean Corpuscular Hemoglobin Concentration ($\text{MCHC} = [\text{Hb} / \text{Hct}] \times 100$) increases, often exceeding the physiological threshold of $36.0\text{ g/dL}$.
• Falsely Decreased ESR: Hypertonic cell shrinkage and altered membrane charge prevent erythrocytes from stacking into rouleaux columns, leading to a markedly depressed Erythrocyte Sedimentation Rate.
• Platelet Swelling and Disintegration: Excess EDTA induces progressive platelet ballooning, fragmentation, and disintegration into microparticles that can be erroneously registered as microcytic erythrocytes or background noise.

Analytical Effects of Tube Overfilling

Overfilling occurs when vacuum tubes are forced beyond their intended capacity or when blood is transferred from a syringe without respecting the fill line:

• Inadequate Anticoagulation: Insufficient EDTA concentration allows trace thrombin generation.
• Fibrin Microclots: Incomplete anticoagulation generates microscopic fibrin strands that entrap platelets and leukocytes.
• Pseudothrombocytopenia and Pseudoleukopenia: Platelets and white blood cells consumed within microclots are excluded from automated counts, yielding dangerously false thrombocytopenia and leukopenia.
• Aperture Clogging: Microclots obstruct analyzer hydraulic chambers and counting orifices, triggering recurrent sensor error flags.

---

2. Sodium Citrate (3.2%, 0.109 M) and Coagulation Specimen Quality

While EDTA is optimal for cell morphology, it irreversibly denatures coagulation Factors V and VIII and binds calcium so tightly that it cannot be consistently overcome by calcium re-addition. Therefore, buffered sodium citrate is the mandatory anticoagulant for coagulation diagnostics.

                         ┌────────────────────────────────────────────────────────┐
                         │   Sodium Citrate Tube Mechanics (9:1 Whole Blood/AC)   │
                         └───────────────────────────┬────────────────────────────┘
                                                     │
                      ┌──────────────────────────────┴──────────────────────────────┐
                      ▼                                                             ▼
       ┌───────────────────────────────┐                             ┌───────────────────────────────┐
       │   Normal Patient (Hct 40%)    │                             │  Polycythemic Patient (Hct 65%)│
       ├───────────────────────────────┤                             ├───────────────────────────────┤
       │ Total Blood Draw: 4.5 mL      │                             │ Total Blood Draw: 4.5 mL      │
       │ • Plasma Volume: 2.7 mL       │                             │ • Plasma Volume: 1.575 mL     │
       │ • Citrate Volume: 0.5 mL      │                             │ • Citrate Volume: 0.5 mL      │
       │ • Ratio: Citrate / Plasma OK  │                             │ • Ratio: Citrate / Plasma ↑↑  │
       └──────────────┬────────────────┘                             └──────────────┬────────────────┘
                      │                                                             │
                      ▼                                                             ▼
       ┌───────────────────────────────┐                             ┌───────────────────────────────┐
       │ Calcium in PT/aPTT Reagent    │                             │ Excess Unchelated Citrate     │
       │ Overcomes Citrate Exactly     │                             │ Neutralizes Reagent Calcium   │
       ├───────────────────────────────┤                             ├───────────────────────────────┤
       │ Result: Accurate Clot Times   │                             │ Result: Falsely Prolonged PT  │
       └───────────────────────────────┘                             └───────────────────────────────┘

Standard 9:1 Blood-to-Anticoagulant Ratio

Per CLSI guideline H21-A5, coagulation testing requires 3.2% (0.109 mol/L) buffered sodium citrate. The liquid anticoagulant must maintain an exact ratio of 9 parts whole blood to 1 part anticoagulant (e.g., $4.5\text{ mL}$ blood added to $0.5\text{ mL}$ citrate, or $2.7\text{ mL}$ blood to $0.3\text{ mL}$ citrate, yielding a $10\%$ anticoagulant fraction by total volume).

Mechanism of Underfilling in Citrate Tubes

Underfilling a citrate tube is one of the most common causes of specimen rejection in the clinical laboratory:

1. If a tube is filled to only half its intended volume, the ratio of liquid citrate to blood becomes excessive ($4:1$ or $5:1$ instead of $9:1$).
2. The excess, unchelated citrate remains dissolved in the patient's plasma.
3. During automated Prothrombin Time (PT) and activated Partial Thromboplastin Time (aPTT) testing, a standardized, fixed concentration of calcium chloride ($0.025\text{ M } CaCl_2$) is added to initiate clotting.
4. The surplus free citrate in the patient's plasma rapidly chelates the reagent's added calcium.
5. Fibrin polymerization is markedly delayed, producing falsely prolonged PT and aPTT results, which may prompt inappropriate administration of fresh frozen plasma or withholding of critical anticoagulation therapy.

Hematocrit Correction for Polycythemic Patients

The 9:1 whole blood-to-citrate ratio is calibrated for individuals with normal hematocrits ($35\%\text{ to }45\%$). Coagulation factors reside exclusively in the plasma fraction, not in erythrocytes.

When a patient has extreme erythrocytosis or polycythemia with a hematocrit exceeding 55%, the relative plasma volume per milliliter of whole blood is sharply reduced. Consequently, a standard volume of 3.2% citrate provides an overwhelming excess of anticoagulant relative to the small plasma volume. This excess citrate chelates the testing reagent calcium, causing falsely prolonged clotting times.

To prevent this, the volume of sodium citrate in the collection tube must be mathematically adjusted prior to phlebotomy using the standardized CLSI formula:

$C = 1.85 \times 10^{-3} \times (100 - \text{Hct}) \times V_{\text{blood}}$

$\text{Alternatively written as: } C = 0.00185 \times (100 - \text{Hct}) \times V_{\text{blood}}$

Where:

• $C$ = Volume of 3.2% sodium citrate remaining in the tube (in $\text{mL}$)
• $\text{Hct}$ = Patient's hematocrit (expressed as a whole percentage, e.g., 65)
• $V_{\text{blood}}$ = Volume of whole blood to be added to the tube (in $\text{mL}$)

Step-by-Step Clinical Calculation:

A polycythemic patient with a hematocrit of $65\%$ requires PT and aPTT monitoring. The laboratory utilizes standard $5.0\text{ mL}$ draw tubes that normally contain $0.5\text{ mL}$ of citrate and require $4.5\text{ mL}$ of blood ($V_{\text{blood}} = 4.5\text{ mL}$):

1. Substitute values into the equation: $C = 0.00185 \times (100 - 65) \times 4.5$
2. Perform arithmetic: $C = 0.00185 \times 35 \times 4.5 = 0.06475 \times 4.5 = 0.291\text{ mL}$
3. Laboratory Action: The technologist opens a standard tube containing $0.50\text{ mL}$ of citrate, aspirates and discards $0.21\text{ mL}$ ($0.50 - 0.29 = 0.21\text{ mL}$), leaving exactly $0.29\text{ mL}$ of citrate in the tube. The phlebotomist then draws exactly $4.5\text{ mL}$ of whole blood into this adjusted tube, completely eliminating the preanalytical artifact.

---

3. Preanalytical Artifacts: EDTA-Dependent Pseudothrombocytopenia

EDTA-dependent pseudothrombocytopenia is a benign, in vitro phenomenon occurring in approximately $0.1\%\text{ to }0.2\%$ of the general population and up to $2\%$ of hospitalized inpatients.

  EDTA-Dependent Pseudothrombocytopenia Pathophysiological Cascade:
  ┌────────────────────────────────────────────────────────────────────────┐
  │ Normal In Vivo Platelet: GP IIb/IIIa (αIIbβ3) requires Ca2+ for shape  │
  └───────────────────────────────────┬────────────────────────────────────┘
                                      │
                                      ▼ Blood drawn into EDTA
  ┌────────────────────────────────────────────────────────────────────────┐
  │ EDTA chelates ionized Ca2+ ──► Structural conformational change        │
  │ Dissociation of GP IIb/IIIa exposes cryptic "hidden" neo-epitopes      │
  └───────────────────────────────────┬────────────────────────────────────┘
                                      │
                                      ▼ In vitro reaction
  ┌────────────────────────────────────────────────────────────────────────┐
  │ Patient's cold-reacting autoantibodies (IgG/IgM/IgA) bind neo-epitopes │
  │ Massive platelet agglutination + Satellitism around mature Neutrophils │
  └───────────────────────────────────┬────────────────────────────────────┘
                                      │
                                      ▼ Automated Analyzer Result
  ┌────────────────────────────────────────────────────────────────────────┐
  │ • Platelet clumps sized > 35 fL ──► Counted as Small Lymphocytes       │
  │ • Severe False Thrombocytopenia (e.g., PLT 12,000/µL) + False Lympho   │
  └────────────────────────────────────────────────────────────────────────┘

Immunological Mechanism and Platelet Satellitism

1. Under physiological in vivo conditions, platelet surface glycoprotein IIb/IIIa (integrin $\alpha_{IIb}\beta_3$) is a calcium-dependent heterodimer essential for fibrinogen binding.
2. When whole blood is collected into EDTA, the rapid chelation of $Ca^{2+}$ destabilizes the heterodimer complex, inducing a conformational change that exposes cryptic (normally hidden) peptide sequences on GP IIb.
3. In susceptible individuals, circulating cold-reacting autoantibodies—predominantly IgG, but occasionally IgM or IgA—directed against these cryptic epitopes bind to the altered receptors at room temperature ($20\text{--}25^\circ\text{C}$).
4. The autoantibodies cross-link adjacent platelets, resulting in large, dense platelet agglutinates.
5. Simultaneously, the Fc portion of these platelet-bound antibodies binds to Fc$\gamma$RIII receptors on the surfaces of mature neutrophils and bands, producing platelet satellitism (satellitosis), where rosettes of 4 to 20 platelets surround neutrophil membranes.

Analyzer Impact and Diagnostic Danger

Automated impedance and optical cell counters evaluate platelets within a strict electronic volume threshold (typically $2\text{ to }20\text{ fL}$ or $2\text{ to }30\text{ fL}$):

• Platelet agglutinates composed of tens or hundreds of platelets possess aggregate volumes exceeding $35\text{ to }50\text{ fL}$.
• The analyzer excludes these clumps from the platelet aperture and misclassifies them as small lymphocytes or unlysed debris.
• This produces a devastatingly false low platelet count (often $< 20,000/\mu\text{L}$), accompanied by a subtle artifactual pseudolymphocytosis.
• Unrecognized pseudothrombocytopenia has historically led to unnecessary bone marrow biopsies, high-dose corticosteroid therapy for misdiagnosed Immune Thrombocytopenia (ITP), and cancelled elective surgeries.

Standard Laboratory Resolution Protocol

When an unexplained low platelet count occurs, the technologist must execute the following corrective algorithm:

  Suspected Pseudothrombocytopenia Workflow:
  ┌────────────────────────────────────────────────────────┐
  │ 1. Examine Wright-stained peripheral blood smear       │
  │    Confirm platelet clumps and/or neutrophil rosettes  │
  └───────────────────────────┬────────────────────────────┘
                              │
                              ▼ Clumps Confirmed
  ┌────────────────────────────────────────────────────────┐
  │ 2. Order immediate redraw in 3.2% Sodium Citrate tube  │
  │    (Alternative: Heparin or pre-warmed capillary smear)│
  └───────────────────────────┬────────────────────────────┘
                              │
                              ▼ Process on Analyzer
  ┌────────────────────────────────────────────────────────┐
  │ 3. Automated Platelet Count obtained on Citrate tube   │
  │    Multiply result by 1.1 (Dilution Correction Factor) │
  └───────────────────────────┬────────────────────────────┘
                              │
                              ▼ Final Review
  ┌────────────────────────────────────────────────────────┐
  │ 4. Verify smear from citrate tube is clump-free        │
  │    Report corrected count with technologist comment    │
  └────────────────────────────────────────────────────────┘

1. Peripheral Blood Film Review: Always examine the feathered edge and lateral borders of a Wright-stained smear under low power ($10\times$). Platelet clumps preferentially migrate to the smear perimeter.
2. Sodium Citrate Redraw: Collect a new blood specimen in a light blue-top tube containing 3.2% sodium citrate. Calcium is bound less aggressively, typically preventing the conformational change in GP IIb/IIIa.
3. Application of Dilution Factor: Because liquid sodium citrate dilutes whole blood by $10\%$ (9 parts blood to 1 part anticoagulant), the automated platelet count generated from the citrate tube must be multiplied by a factor of 1.1: $\text{True Platelet Count} = \text{Automated Citrate Platelet Count} \times 1.1$
4. Smear Verification: Check a smear prepared from the citrate tube to confirm complete dispersal of clumps.
5. Alternative Measures: If clumping persists in citrate, redraw in sodium heparin or collect an unanticoagulated capillary fingerstick blood smear for direct manual phase-contrast hemocytometer enumeration.

---

4. Specimen Stability, Smear Timing, and Storage Artifacts

Blood is a living tissue that undergoes ongoing metabolic activity, autolysis, and osmotic alteration following venipuncture.

The Critical Smear Preparation Window

CLSI guidelines mandate that peripheral blood smears be prepared within 2 to 4 hours of venipuncture. Storage beyond 4 hours at room temperature produces progressive morphological deterioration that invalidates differential counts.

  Time-Dependent Cellular Degeneration in Stored EDTA Blood:
  ┌──────────────────────────────────────────────────────────────────────────┐
  │ 0 to 2 Hours: Pristine morphology; sharp granules; normal RBC biconcavity│
  ├──────────────────────────────────────────────────────────────────────────┤
  │ 4 Hours: RBC crenation begins; minor neutrophil nuclear lobulation shifts │
  ├──────────────────────────────────────────────────────────────────────────┤
  │ 6 to 8 Hours: Neutrophil nuclear pyknosis (homogeneous dark spheres);    │
  │ monocyte and neutrophil cytoplasmic vacuolation (pseudo-toxic change)    │
  ├──────────────────────────────────────────────────────────────────────────┤
  │ > 12 to 24 Hours: Necrobiotic cells; cloverleaf nuclei; erythrocyte      │
  │ spherocytosis; marked platelet swelling and automated MCV elevation      │
  └──────────────────────────────────────────────────────────────────────────┘

Morphological Artifacts in Stored EDTA Blood

1. Erythrocyte Alterations:

   • Echinocyte Formation (Crenation): As intracellular ATP levels decline, the active extrusion of calcium ceases and lipid asymmetry in the cell membrane is lost, transforming normal biconcave discocytes into scalloped echinocytes featuring 10 to 30 blunt, regular surface spicules.
   • Osmotic Spherocytosis: With prolonged standing, the loss of selective membrane permeability causes erythrocytes to lose their central biconcave pallor and assume a spherical shape.

2. Leukocyte Alterations:

   • Nuclear Pyknosis and Karyorrhexis: Leukocyte nuclei condense into dense, structureless, intensely dark spheres (pyknosis) or fragment into multiple spherical apoptotic droplets (karyorrhexis). This can cause pyknotic neutrophils to be misidentified as nucleated red blood cells (orthochromic normoblasts).
   • Cytoplasmic Vacuolation: Neutrophils and monocytes develop prominent, clean-edged cytoplasmic vacuoles. In an unpreserved or delayed specimen, this is an in vitro artifact of autolysis, but it is frequently misdiagnosed as true toxic vacuolation secondary to severe sepsis.
   • Cloverleaf or Radial Nuclear Segmentation: Monocyte and lymphocyte nuclei undergo bizarre lobulation, folding into cloverleaf structures.
   • Smudge Cells / Necrobiotic Debris: Fragile degenerated leukocytes rupture during slide spreading, generating unclassifiable necrobiotic debris.

3. Platelet Artifacts:

   • Progressive degranulation and swelling, forming oversized, pale-staining giant platelets or disintegrating into particulate debris.

Storage Temperature and CBC Parameter Stability

When immediate testing is impossible, specimens must be handled according to temperature-dependent kinetics:

---

5. Preanalytical Errors and Corrective Protocols Summary